CONCLUSION: Our data suggest that plasma p-tau217 is a suitable screening method for clinical trials in CU populations given its logistic advantages. In scenarios where a more refined prediction of cognitive decline is mandated, Tau-PET (preferably in a combined algorithm with plasma p-tau217) would be the methodology of …